Chase Investment Counsel Corp Trims Holdings in HealthEquity, Inc. (NASDAQ:HQY)

Chase Investment Counsel Corp cut its stake in HealthEquity, Inc. (NASDAQ:HQY - Free Report) by 85.5% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 5,923 shares of the company's stock after selling 35,063 shares during the period. Chase Investment Counsel Corp's holdings in HealthEquity were worth $484,000 as of its most recent SEC filing.

Other hedge funds have also recently bought and sold shares of the company. Carrera Capital Advisors bought a new stake in shares of HealthEquity during the third quarter valued at approximately $1,299,000. GSA Capital Partners LLP bought a new stake in shares of HealthEquity during the third quarter worth $638,000. GDS Wealth Management bought a new position in shares of HealthEquity in the 3rd quarter worth $2,344,000. Los Angeles Capital Management LLC boosted its position in shares of HealthEquity by 92.3% during the third quarter. Los Angeles Capital Management LLC now owns 55,597 shares of the company's stock worth $4,551,000 after purchasing an additional 26,690 shares in the last quarter. Finally, Covestor Ltd grew its position in shares of HealthEquity by 27.4% in the 3rd quarter. Covestor Ltd now owns 1,524 shares of the company's stock valued at $125,000 after purchasing an additional 328 shares during the period. 99.55% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of equities analysts have weighed in on HQY shares. Royal Bank of Canada reissued an "outperform" rating and set a $92.00 price target on shares of HealthEquity in a research report on Wednesday, September 4th. Bank of America increased their price target on HealthEquity from $100.00 to $120.00 and gave the company a "buy" rating in a research note on Wednesday. Deutsche Bank Aktiengesellschaft lifted their price objective on shares of HealthEquity from $102.00 to $103.00 and gave the stock a "buy" rating in a research report on Wednesday, September 4th. JMP Securities reissued a "market outperform" rating and issued a $105.00 price target on shares of HealthEquity in a report on Wednesday, September 4th. Finally, Barrington Research restated an "outperform" rating and set a $105.00 price objective on shares of HealthEquity in a report on Friday, September 20th. Twelve investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has an average rating of "Buy" and an average price target of $105.50.

HealthEquity Price Performance

Shares of NASDAQ:HQY traded down $5.48 during midday trading on Wednesday, hitting $94.72. The stock had a trading volume of 659,354 shares, compared to its average volume of 614,480. The company has a quick ratio of 4.10, a current ratio of 4.10 and a debt-to-equity ratio of 0.51. The company has a market capitalization of $8.27 billion, a P/E ratio of 79.59, a price-to-earnings-growth ratio of 1.57 and a beta of 0.52. The company's 50-day moving average price is $84.00 and its 200-day moving average price is $80.74. HealthEquity, Inc. has a fifty-two week low of $62.10 and a fifty-two week high of $101.17.

HealthEquity (NASDAQ:HQY - Get Free Report) last issued its earnings results on Tuesday, September 3rd. The company reported $0.66 earnings per share for the quarter, beating analysts' consensus estimates of $0.50 by $0.16. HealthEquity had a return on equity of 9.01% and a net margin of 9.61%. The firm had revenue of $299.93 million for the quarter, compared to the consensus estimate of $284.48 million. As a group, equities research analysts predict that HealthEquity, Inc. will post 2.27 EPS for the current fiscal year.

Insider Buying and Selling at HealthEquity

In related news, Director Frank Corvino sold 1,039 shares of the stock in a transaction that occurred on Wednesday, November 6th. The shares were sold at an average price of $96.10, for a total value of $99,847.90. Following the completion of the transaction, the director now owns 3,784 shares of the company's stock, valued at $363,642.40. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In related news, Director Robert W. Selander sold 8,250 shares of the company's stock in a transaction that occurred on Wednesday, October 9th. The stock was sold at an average price of $82.98, for a total value of $684,585.00. Following the transaction, the director now owns 54,719 shares in the company, valued at approximately $4,540,582.62. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Frank Corvino sold 1,039 shares of the stock in a transaction on Wednesday, November 6th. The stock was sold at an average price of $96.10, for a total value of $99,847.90. Following the transaction, the director now owns 3,784 shares of the company's stock, valued at $363,642.40. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 10,536 shares of company stock worth $884,517 over the last 90 days. Insiders own 2.20% of the company's stock.

HealthEquity Company Profile

HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.